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Abstract
Background: Cholesterol deposition in arterial wall drives atherosclerosis. The key goal of this study was to examine 
the relationship between plaque cholesterol content and patient characteristics that typically associate with disease 
state and lesion vulnerability. Quantitative assays for free cholesterol, cholesteryl ester, triglyceride, and protein markers 
in atherosclerotic plaque were established and applied to plaque samples from multiple patients and arterial beds 
(Carotid and peripheral arteries; 98 lesions in total).
Results: We observed a lower cholesterol level in restenotic than primary peripheral plaque. We observed a trend 
toward a higher level in symptomatic than asymptomatic carotid plaque. Peripheral plaque from a group of well-
managed diabetic patients displayed a weak trend of more free cholesterol deposition than plaque from non-diabetic 
patients. Plaque triglyceride content exhibited less difference in the same comparisons. We also measured cholesterol 
in multiple segments within one carotid plaque sample, and found that cholesterol content positively correlated with 
markers of plaque vulnerability, and negatively correlated with stability markers.
Conclusions: Our results offer important biological validation of cholesterol as a key lipid marker for plaque severity. 
Results also suggest cholesterol is a more sensitive plaque marker than routine histological staining for neutral lipids.
Background
Atherosclerosis is a chronic disease characterized by lipid
deposition and inflammation in the arterial wall[1]. Cho-
lesterol is the major lipid species in atherosclerotic
lesions and accumulates in both unesterified and esteri-
fied forms[2]. Early studies characterizing localization
and abundance of cholesterol in association with lesion
morphology and severity have illuminated the prominent
role of cholesterol in athero-progression. Rapp et al.
observed that an increased percentage of free cholesterol
(as a proportion of total cholesterol) was associated with
evolution of the atherosclerotic process[3]. Kruth further
demonstrated that free and esterified cholesterol accu-
mulated within many diverse and distinct structures in
lesions, and extracellular free cholesterol-enriched parti-
cles constituted a significant portion of accumulated cho-
lesterol[4]. Klemp et al. found that lesion cores showed an
increase in the percentage of free cholesterol, whereas
lesion caps were more enriched in cholesteryl ester[5].
These studies in aggregate suggest that deposition of free
and esterified cholesterol has a critical physiological
impact on athero-progression.
A large body of evidence supporting cholesterol's cen-
tral role in atherosclerosis was generated using his-
tochemical analysis with lipid-soluble Sudan dyes such as
Oil Red O (ORO). These dyes stain neutral lipids includ-
ing cholesteryl ester and triglyceride, but they do not
stain free cholesterol[6]. Nonetheless, such stains in
human plaque have demonstrated that lipid enrichment
is usually associated with higher degrees of inflammation
and characteristics of plaque vulnerability[7].
In addition to being a key driver for atherosclerosis,
cholesterol is dynamically modulated in lesion regression
or stabilization. A robust reduction in free and esterified
cholesterol in response to treatment with certain agents
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has been observed in animal studies[8-10]. In clinical
studies, although quantitation of lesion cholesterol has
not been utilized as study outcome, histological analyses
have demonstrated that certain therapies, such as statins,
can result in reduction in lipid-rich region in lesions[11].
In our effort of using plaque as a quantitative platform
for studying effect of novel therapeutic entities in
humans, we sought to explore the relationship between
plaque cholesterol content and patient characteristics
that have been implicated in lesion pathogenesis. We ana-
lyzed free and esterified cholesterol levels, along with
other lipid and protein markers, in lesions from three
stratified patient cohorts. Correlations between choles-
terol levels and patient characteristics constitute key
results in this report. We also provide an analysis of cho-
lesterol content in different segments within one plaque
as additional validation of our approach.
Methods
Human atherosclerotic lesions
For the restenotic vs. primary plaque comparison, 11
restenotic plaques and 36 primary plaques were obtained
through atherectomy with the Silverhawk apparatus
(EV3, Inc.) from lower extremity of patients. Samples
were flash frozen and stored at -80°C till processing. For
the diabetic (DM) vs. non-diabetic (non-DM) compari-
son, peripheral plaques from 14 DM patients and 16 non-
DM patients were obtained through the Silverhawk appa-
ratus. Diabetic status was based on patient report at the
time of atherectomy. Additional patient characteristics
are described in Table 1. Samples were collected into
RNAlater solution (Qiagen) and stored at -20°C till pro-
cessing. For the symptomatic vs. asymptomatic compari-
son, plaques from 8 symptomatic patients (75 ± 7 years of
age, 7 males) and 12 asymptomatic patients (71 ± 13 years
of age, 6 males) were obtained through carotid endart-
erectomy. The plaques were categorized by the patient's
physician as either symptomatic or asymptomatic accord-
ing to patient's history and clinical examination. Samples
were collected into RNAlater and stored at -20°C till pro-
cessing. For the sub-plaque analysis, one plaque was
obtained from a carotid endarterectomy patient at Ellis
Hospital (Schenectady NY), embedded and stored frozen
in Optimal Cutting temperature (OCT) solution until
processing. Institutional Review Board (IRB) approval
was obtained and patients gave informed consent for use
of their plaque tissues in studies of tissue biomarkers.
Protein extraction and measurement
RNAlater-stored plaques were removed from RNAlater
and powderized by TissueLyser (Qiagen) at -80°C before
processing for protein. Flash frozen plaques were pulver-
ized by Covaris Tissue CryoPrep system (Covaris, Inc.) at
-80°C before processing for protein. Tissue slices from the
OCT-embedded carotid plaque were also pulverized.
Protein in the pulverized or powderized samples were
extracted with PBS + 1%CHAPS in the Covaris E210 tis-
sue extraction system and stored at -80°C until assay. Pel-
lets were stored at -80°C until processing for lipids. CD68
was measured using an immunoassay developed for
human CD68. The calibrator for the assay was a lysate of
the macrophage cell line THP-1, hence the results of
CD68 measurement are expressed as μg of THP-1 lysate.
ICAM-1 levels were determined by Rules Based Medicine
Human MAP multi-analyte analysis. Lumican and
Smooth Muscle Myosin Heavy Chain (SMMHC) levels
were determined by Western blotting, with the goat anti-
Lumican (R&D Systems) and mouse anti-SMMHC
(Dako) used as primary antibodies. Cathepsin B was mea-
sured by an immunoassay from R&D Systems.
Lipid extraction and measurement
Pellets resulted from protein extraction were subjected to
lipid extraction by the Folch method[12]. For cholesterol
measurement, lipid extracts were spotted onto 96-well
plates, dried, and resolubilized in ethanol. To measure
free cholesterol, samples were incubated for 1 hour at
37°C in a reaction mixture that includes cholesterol oxi-
dase, peroxidase, and p-hydroxyphenylacetic acid, with
the fluorescent product measured in a Tecan GENios Pro.
Cholesterol esterase (Calbiochem) was included in sepa-
rate reactions for measuring total cholesterol. Cholesteryl
ester content was derived by subtracting free cholesterol
from total cholesterol. For triglyceride measurement,
lipid extracts were spotted onto 96-well plates, dried, and
resolubilized in 4% Triton X-100. Triglyceride assay
reagent (Roche) was then added to each well to allow
reaction at room temperature for 10 minutes, with the
colorimetric product measured in a Spectra Max 250
(Molecular Devices).
Histology and immunohistochemistry
10 μm tissue sections were generated from the OCT-
embedded plaque by Cryostat. Hemotoxylin & eosin
Table 1: Patient Characteristics of the Diabetic (DM) and 
Non-diabetic (non-DM) Groups
Patient data Non-DM DM P value
Male gender (total) 10 (16) 7 (14) N/A
smoking (total) 12 (16) 10 (14) N/A
age, years 73+/-10 72+/-13 >0.1
HbA1C 5.8+/-0.7 7.1+/-1.5 0.003
Total Cholesterol, mg/dL 189+/-58 154+/-26 0.05
HDL, mg/dL 52+/-21 39+/-13 0.06
LDL, mg/dL 104+/-35 86+/-23 >0.1
Triglycerides, mg/dL 196+/-150 145+/-85 >0.1Chen et al. Lipids in Health and Disease 2010, 9:61
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(H&E) staining was performed by routine methods.
Mouse anti-CD68 (Neomarkers, Ab-3) and mouse anti-
SMMHC (Neomarkers, SMMS-1) were used for immu-
nohistochemistry for CD68 and SMMHC, respectively.
Data Analyses
For all whole plaque samples, the analytes' values were
normalized to tissue weight. Cholesterol and triglyceride
were expressed as nmol/mg tissue, and Lumican was
expressed in units of AU (arbitrary unit) per mg tissue.
For the OCT-embedded plaque slices, the analytes' values
were normalized to total protein. Cholesterol and triglyc-
eride were expressed as nmol/mg protein; ICAM-1,
CD68, SMMHC were expressed as ng/mg protein, μg
THP-1/mg protein, and AU/mg protein, respectively. T-
tests were generated using Microsoft Excel's functions.
For comparison between patient groups, natural loga-
rithm transformation was applied to the normalized ana-
lytes' levels to meet the normality assumption for
statistical analyses.
Results
Restenotic plaque had lower cholesterol content than 
primary plaque
Several studies have indicated restenotic plaques are fre-
quently associated with lower prevalence of large lipid
core and inflammation compared with primary
lesions[13,14], although specific comparison of choles-
terol content has not been reported. We measured cho-
lesterol content in 11 restenotic and 36 primary
peripheral plaques, and observed significantly less total
cholesterol (TC) (Fig. 1A), free cholesterol (FC) (Fig. 1B),
and cholesteryl ester (CE) (Fig. 1C) in the restenotic
group. Triglyceride (TG) trended toward a lower level in
the restenotic group without reaching statistical signifi-
cance (Fig.1D). CD68, a marker for macrophage content,
was not distinguishable between the two groups (Fig. 1E),
whereas Cathepsin B, a protease that has been linked to
plaque inflammation and vulnerability[15], was signifi-
cantly lower in the restenotic group (Fig. 1F). These
results suggest that although macrophage content was
similar between the two groups, macrophages in rest-
enotic plaque may display less inflammatory and prote-
olytic activities.
Since it is known that restenotic plaque has proteogly-
can-enriched extracellular matrix[16], we were curious
about a small soluble proteoglycan, Lumican, in this
study. Lumican was previously characterized as dynami-
cally present in various stages of lesion progression and
potentially involved in smooth muscle prolifera-
tion[17,18]. Our analysis revealed Lumican was highly
abundant in plaque samples, with its SDS-PAGE migra-
tion pattern similar to previously observed[17] (Fig. 1G);
restenotic lesions had significantly more Lumican than
primary lesions (Fig. 1H), suggesting that Lumican may
indeed be involved in the smooth muscle cell prolifera-
tion process underlying restenosis.
Symptomatic carotid plaque trended toward more 
cholesterol deposition than asymptomatic plaque
We measured cholesterol, triglyceride, and inflammatory
protein markers in carotid plaques from 8 symptomatic
patients (those with a history of neurological symptoms
attributable to carotid atherosclerosis) and 12 asymptom-
atic patients. TC (Fig. 2A) and FC (Fig. 2B) trended
toward a higher level in symptomatic plaque, with their
p-values approaching statistical significance. CE (Fig. 2C)
and TG (Fig. 2D) exhibited a similar, albeit weaker, trend.
The fact that FC was more distinguishable than CE
between the two groups is consistent with the under-
standing that accumulated FC is highly toxic and contrib-
utes to lesion progression and instability[3]. Our results
also demonstrated that among the major lipid species in
plaque, cholesterol had a stronger correlation with cere-
brovascular events than triglyceride, which is consistent
with the notion that cholesterol is the primary driver for
atherosclerosis.
Cholesterol content in diabetic vs. non-diabetic peripheral 
plaques
Diabetic patients are at a high risk for cardiovascular
events compared with non-diabetics with similar athero-
sclerotic burden[19], and several studies have found fea-
tures of plaque vulnerability in diabetic patients,
including increased lipid and macrophage content and
decreased collagen content[20,21]. We examined choles-
terol content in peripheral plaque samples from 14 dia-
betic and 16 non-diabetic patients. TC (Fig. 3A) and CE
(Fig. 3B) were barely distinguishable between the two
groups. FC displayed a weak trend toward higher deposi-
tion in the diabetic group (Fig. 3C). FC to CE ratio was
significantly higher in the diabetic group (Fig. 3D), sug-
gesting those lesions may be more advanced. TG content
was indistinguishable between the two groups (Fig. 3E). It
should be noted that in this cohort of apparently well-
managed patients, lipid profiles of the diabetic group
were not typical of diabetic dyslipidaemia, with their
serum cholesterol and triglyceride levels lower than the
non-diabetic group (Table 1).
Cholesterol analysis in multiple segments within one 
carotid plaque
Atherosclerotic lesions are heterogeneous, and lipid
deposits within a plaque can differ markedly, accompany-
ing distinct local morphological characteristics[5]. We
therefore sought to examine the relationship between
cholesterol levels and morphological and molecular fea-
tures in multiple segments (slices) within one plaque
specimen. An OCT-embedded carotid plaque was seri-Chen et al. Lipids in Health and Disease 2010, 9:61
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Figure 1 47 peripheral plaque samples were sequentially extracted for protein and lipid. TC (A), FC (B), CE (C), TG (D), CD68 (E), Cathepsin B (F), 
and Lumican (G, H) levels in the plaque were determined and compared between restenotic (R) and primary (P) plaques. Bar represents mean.
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Figure 2 20 carotid plaque samples were sequentially extracted for protein and lipid. TC (A), FC (B), CE (C), and TG (D) levels in the plaque were 
determined and compared between the asymptomatic and symptomatic groups. Bar represents mean.
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ally cut into cross-sections on a cryostat, with 300 μm
slices used for protein and cholesterol measurement, and
adjacent thin (10 μm) sections used for histological analy-
ses. Macroscopic and microscopic views of H&E, CD68,
and SMMHC stainings in sections adjacent to and repre-
senting slice#1, 5, and 15, were provided in Fig. 4 and Fig.
5, respectively, for illustration of their key morphological
features. Slice#1 was highly stenosed with intense
SMMHC staining and low CD68 staining, indicating it
was primarily a smooth muscle cell-rich, fibrous segment.
Slice#5 had extensive calcification and strong CD68
staining in a large lipid/necrotic core with an overlaying
fibrous cap. These features, along with its low SMMHC
positivity, suggest it is a vulnerable segment within the
plaque. Slice#15, in comparison, was at the thickened
intima stage with slight calcification, low CD68 staining,
and high SMMHC staining. When we examined lipid dis-
tribution over the segments (Fig. 6A), we observed that
CE and TG had similar distribution patterns; FC overall
tracked with CE except than in the lipid core (slice#5),
where cholesterol clefts were readily discernible (Fig. 5).
In examining the relationships between cholesterol and
protein markers, we found distribution pattern of TC was
opposite to a plaque stability marker, SMMHC (Fig. 6B);
TC distribution was similar to markers of vulnerability,
CD68 (Fig. 6C) and ICAM-1 (Fig. 6D). A second carotid
plaque that lacked a prominent lipid core displayed simi-
lar, albeit less striking correlations, between cholesterol
and inflammatory markers (not shown). Taken together,
our observations demonstrate that cholesterol distribu-
tion pattern fit with its understood physiological impact
and local morphological characteristics.
Figure 3 30 peripheral plaque samples were sequentially extracted for protein and lipid. TC (A), CE (B), FC (C), FC/CE (D), and TG (E) levels were 
determined and compared between the non-diabetic (non-DM) and diabetic (DM) groups. Bar represents mean.
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Cholesterol content in carotid plaque vs. peripheral plaque
In analyzing data from the above described restenotic vs.
primary plaque study, symptomatic vs. asymptomatic
plaque study, and diabetic vs. non-diabetic plaque study,
we also found carotid plaques had significantly more TC
(Fig.7A) and higher percentage of FC than peripheral
plaques (Fig.7B).
Discussion
In this report we made novel observations about human
plaque regarding the relationship between plaque choles-
terol content and a number of clinical parameters that
typically associate with plaque instability. Our findings
confirmed and extended the established understanding
on free and esterified cholesterol in plaque, validated our
approach, and solidified our understanding of atheroscle-
rosis.
In interpreting our results we need to keep in mind that
histopathological features of plaque are modifiable by
multiple additional clinical parameters and risk factors.
For example, a large carotid plaque study by Rothwell and
colleagues showed that key lesion characteristics are
highly influenced by nature and timing of ischemic
events[22], and relationship between lesion characteris-
tics and diabetes displayed a temporal trend as well[23].
Histological features of restenotic plaque are also highly
dynamic and dependent on recurrence interval and clini-
cal presentation, with late restenotic lesion starting to
resemble primary lesion[14]. It is therefore unsurprising
that sample sizes for such binary comparisons are usually
too small and results need to be taken with recognition of
caveats with such a validation approach. Nonetheless, our
observations are consistent with a larger body of litera-
ture on plaque inflammation and lipid deposition in rela-
tion to neurological symptoms, diabetes, and restenosis.
Our observation that carotid plaques had significantly
more TC and higher percentage of FC than peripheral
plaques is consistent with previous findings that carotid
arteries have a higher prevalence of foam cell lesions and
lipid core plaques than peripheral arteries[24]. Our intra-
plaque analysis of cholesterol content in comparison with
protein markers is also consistent with the understanding
of role of cholesterol in plaque vulnerability.
Our specific analyses of FC and CE in the symptomatic/
asymptomatic comparison and DM/non-DM compari-
son suggest FC is a more sensitive marker of plaque
severity than CE. From the perspective of drug effect, in
animal studies, reduction in CE by therapeutic entities
appeared to always exceed reduction in FC[8-10].
Although such comparisons in human lesions are yet to
be reported, it is plausible that we will observe the same
pattern in human drug trials. Main reason for this expec-
tation is that we believe the predominant mechanism of
cholesterol reduction in lesion is cholesterol efflux from
CE-enriched cells and a high percentage of FC in
advanced human lesions exists in the extracellular space
in inaccessible forms. Distinguishing CE from FC is
therefore a highly desirable capability of our platform.
Animal studies also suggested reduction in CE by drug
treatment could exceed reduction in triglyceride[8]. Since
both CE and triglyceride stain positive with ORO , our
results together with available literature evidence suggest
specific quantitation of FC and CE may allow us better
sensitivity in gauging plaque severity and drug effect than
neutral lipids staining with ORO.
Our cholesterol analyses across different arterial beds
and patient groups have also added a value to our plat-
form-building effort in that they provided a new dimen-
sion in assessing protein and RNA biomarkers. Indeed,
Figure 4 A carotid plaque was alternately sectioned to allow his-
tological, protein, and lipid analyses. Macroscopic views of H&E, 
CD68, and SMMHC stainings for selected slices are shown.
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Figure 5 High-power view of the insets in Fig. 4.
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through plaque splitting, which allows parallel measure-
ment of cholesterol, protein, and RNA markers within
one tissue sample (manuscript submitted), we have iden-
tified a host of protein markers and gene expression sig-
natures that correlate with cholesterol deposition (not
shown). Further analysis of these findings will not only
validate our approach but also yield new insight on the
complex plaque biology. Our lipid extraction and choles-
terol measurements also opened the door to establishing
and evaluating additional plaque lipid components that
are potentially implicated in lesion progression. Finally,
our results could also serve as an important benchmark
for assessing various newly-emerged imaging modalities
that bear the promise of quantitating lipid content in
plaque.
Conclusions
We have integrated cholesterol measurement into our
human plaque analysis as a potential platform for reading
drug effect. Our studies, to our best knowledge, mark the
first effort of correlating plaque cholesterol content,
including free and esterified cholesterol, with multiple
patient characteristics. Our findings demonstrate that
specific and quantitative analysis of cholesterol serves as
an excellent marker for plaque vulnerability and poten-
tially a very suitable endpoint for measuring drug effect.
Clinical studies in which we will measure a comprehen-
sive endpoint that includes plaque cholesterol, protein,
RNA, and imaging parameters in response to drug treat-
ment are under way. Results also support the notion that
Figure 6 (A) TG and cholesterol levels over the segments. (B-D) SMMHC, CD68, and ICAM-1 levels in comparison to TC.
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deposition of cholesterol, in particular free cholesterol, in
human atherosclerotic plaque, is a marker for underlying
disease state and lesion progression.
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